Drug news

Phase III results of PRT 4445 (andexanet alfa) as an antidote were published in the New England Journal of Medicine- Portola Pharmaceuticals

Read time: 1 mins

Last updated:12th Nov 2015

Published:12th Nov 2015

Source: Pharmawand

Portola Pharmaceuticals announced that the results of its Phase III ANNEXA study of PRT 4445 (andexanet alfa) as an antidote to Factor Xa inhibitors were published online by The New England Journal of Medicine. ANNEXA-R and ANNEXA-A evaluated the safety and efficacy of andexanet alfa, an investigational reversal agent. Results showed that both ANNEXA Part 1 (bolus only) and Part 2 (bolus plus continuous infusion) met all primary and secondary efficacy endpoints, including the measurement of reversal Anti-Xa activity (p<0.0001) for both rivaroxaban (Xarelto) and apixaban (Elequis).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test

2 mins

Drug news

Iomab-B (apamistamab) to overcome high-risk TP53 mutation resulting in significant improvement in overall survival in patients with active relapsed refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17

1 min

Drug news

FDA approves Selarsdi (ustekinumab-biosimilar) to treat plaque psoriasis and active psoriatic arthritis

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older

2 min

See all news